## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box to transaction was contract, instruct purchase or sale issuer that is inte affirmative defen 10b5-1(c). See In	made purs ion or writt of equity s inded to sa se condition	uant to a en plan fo securities itisfy the ons of Rule	of the	
 			*	

1. Name and Address of Reporting Person <sup>*</sup> Levine Mark S.			2. Issuer Name <b>and</b> Ticker or Trading Symbol Immunovant, Inc. [ IMVT ]		ionship of Reporting Persor all applicable) Director	Person(s) to Issuer	
		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 02/22/2024	X	Officer (give title below) Chief Legal C	Other (specify below)	
320 W 37TH STREET, 6TH FLOOR			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person			
(Street)					Form filed by More than	One Reporting Person	
NEW YORK	NY	10018			·	g	
(City)	(State)	(Zip)					
		Table I - Non-Deri	vative Securities Acquired, Disposed of, or Beneficia	lly Owr	ned		

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed     3.       Execution Date, if any     Transaction Code (Instr (Month/Day/Year)			4. Securities Ad Disposed Of (D		4 and 5)	5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock <sup>(1)</sup>	02/22/2024		S		2,134	D	\$36.15(2)	301,968	D		

 
 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Der	Title of rivative curity (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)				Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code V (		(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		

## Explanation of Responses:

1. On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on February 17, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.85 - \$36.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

/s/ Eva Renee Barnett, attorney-infact for Mark S. Levine 02/23/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.